Medicare AdvantageCoverageMedium impact
MA06.017aa, Molecular Diagnostics
Independence Blue Cross·Oncology, Pathology·Medical Policy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
This is a reissue of the Medicare Advantage molecular diagnostics policy MA06.017aa, effective October 1, 2025. Since only summary information is provided without specific details about what changed, billing teams should review the full policy document to understand any updates to coverage, prior authorization, or billing requirements for molecular diagnostic testing.
Action Required
By October 1, 2025: Billing team must access the full policy document at the provided URL to review specific changes to molecular diagnostics coverage and billing requirements for Medicare Advantage plans. Update billing procedures, prior authorization requirements, and staff training based on any policy modifications identified in the complete document.